Abstracts tagged "outcomes"

Abstract Number: 1062 • 2016 ACR/ARHP Annual Meeting
Non-Conventional Antiphospholipid Antibodies in Patients with Clinical Obstetrical APS: Prevalence and Pregnancies Treatment Efficacy
ARSENE MEKINIAN¹, Marie Charlotte Bourrienne², LIONEL CARBILLON³, AMELIE BENBARA⁴, SYLVIE CHOLLET MARTIN⁵, AHMED TIGAIZIN³, Francois Montestruc⁶, Olivier Fain⁷ and Pascale Nicaise-Roland⁸, ¹SAINT ANTOINE HOSPITAL, PARIS, France, ²Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, paris, France, ³JEAN VERDIER HOSPITAL, BONDY, France, ⁴JEAN VERDIER HOSPITAL, PARIS, France, ⁵UNITE HYPERSENSIBILITE, PARIS, France, ⁶exystat, PARis, France, ⁷Internal Medicine Department, Saint Antoine Hospital, Paris, France, ⁸Immunology Department, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France
Background/Purpose: To describe the prevalence of non-conventional APL in patients with obstetrical APS pregnancy adverse outcome without conventional APL and the impact of treatment on…
Abstract Number: 1221 • 2016 ACR/ARHP Annual Meeting
Environmental Scan of Rheumatoid Arthritis Patient Registries Around the World: An Omeract Initiative
Natalia V. Zamora¹, Maria A. Lopez-Olivo², Robin Christensen³, Niti Goel^4,5, Lars Erik Kristensen⁶, Vibeke Strand⁷, Jeffrey R. Curtis⁸, Beverly Shea⁹ and Maria Suarez-Almazor¹⁰, ¹Section of Rheumatology and Clinical Immunology, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁴Rheumatology Center of Excellence, Quintiles, Durham, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁷Biopharmaceutical Consultant, Portola Valley, CA, ⁸Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Department of Clinical Epidemiology & Biostatistics, McMaster University, Health Science Centre Hamilton, Ontario, ON, Canada, ¹⁰Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: Patient registries both disease-and drug-based complement information obtained from clinical trials. Long-term outcomes studies can provide information useful for patients. The Agency for Healthcare…
Abstract Number: 1533 • 2016 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Women with Rheumatoid Arthritis : A Systematic Review and Meta-Analyses
Anne-Lise Gaillard¹, Thomas Barnetche² and Thierry Schaeverbeke³, ¹Rhumatologie, CHU Bordeaux Pellegrin, Bordeaux, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Rheumatology Department, Bordeaux Hospital, Bordeaux, France
Background/Purpose: Actually better control of rheumatoid arthritis (RA) activity leads to new interrogations and daily questions about pregnancy. Only few studies have studied pregnancy outcomes…
Abstract Number: 1779 • 2016 ACR/ARHP Annual Meeting
Remission and Low Lupus Disease Activity Status (LLDAS) Protect Lupus Patients from Damage Occurrence: Data from a Multi-Ethnic, Multinational Latin American Lupus Cohort
Manuel Ugarte-Gil^1,2, Daniel Wojdyla³, Guillermo J. Pons-Estel⁴, Luis J. Catoggio⁵, Cristina Drenkard⁶, Judith Sarano⁷, Guillermo Berbotto⁸, Eduardo Borba⁹, Emilia Sato¹⁰, Joao Carlos Brenol¹¹, Oscar Uribe¹², Luis Ramirez¹², Marlene Guibert-Toledano¹³, Loreto Massardo¹⁴, Mario Cardiel¹⁵, Luis H. Silveira¹⁶, Rosa Chacón-Díaz¹⁷, Graciela S. Alarcón¹⁸, Bernado Pons-Estel¹⁹ and GLADEL (Grupo LatinoAmericano de Estudio de Lupus), ¹Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²Universidad Cientifica del Sur, Lima, Peru, ³GLADEL consultant, Rosario, Argentina, ⁴Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina, ⁶Emory University School of Medicine, Atlanta, GA, ⁷Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ⁸Sanatorio Británico, Rosario, Argentina, ⁹Faculdade de Medicina, Hospital das Clínicas. Universidade de São Paulo, São Paulo, Brazil, ¹⁰Rheumatology Division. Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ¹¹Hospital das Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre - RS, Brazil, ¹²Hospital Universitario “San Vicente de Paul”, Universidad de Antioquia, Medellín, Colombia, ¹³Rheumatology, Centro de Investigaciones Médico Quirúrgicas, Habana, Ciudad Habana, Cuba, ¹⁴Departments of Immunology & Rheumatology, Pontificia Universidad Católica de Chile, Santiago, Chile, ¹⁵Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ¹⁶Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ¹⁷Servicio de Reumatología, Hospital Universitario de Caracas, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, ¹⁸Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁹Sanatorio Parque, Rosario, Argentina
Background/Purpose: Recently, definitions of both Remission and LLDAS have been proposed which include disease activity status and medication intake [immunosuppressive (IS) drugs and corticosteroids]. The…
Abstract Number: 442 • 2015 ACR/ARHP Annual Meeting
Use of Adjunctive Neuroregulatory Medication to Improve Etanercept Treatment Response for Patients with Inflammatory Arthritis: A Pilot Study
Andrew Holman¹ and Edmund Ng², ¹Inmedix, Normandy Park, WA, ²Statistical Thinking, Seattle, WA
Background/Purpose: As a proposed inflammatory biomarker for autoimmune disease1,2, the autonomic nervous system (ANS) has been assessed as a predictor of anti-TNF treatment outcome3 and…
Abstract Number: 2938 • 2015 ACR/ARHP Annual Meeting
Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort
Kichul Ko¹, Alana B. Levine², Russell Griffin³, Olga Dvorkina⁴, Saira Sheikh⁵, Jinoos Yazdany⁶, Richard Furie⁷ and Cynthia Aranow⁸, ¹Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, SUNY Health Science Center at Brooklyn, Brooklyn, NY, ⁵University of North Carolina, Chapel Hill, NC, ⁶Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Division of Rheumatology, North Shore - LIJ Health System, New York, NY, ⁸Feinstein Institute for Medical Research, Mahasset, NY
Background/Purpose: Treating to a target of remission or low disease activity state (LDAS) is an attractive potential therapeutic approach in SLE. Recently, LDAS and remission…
Abstract Number: 567 • 2015 ACR/ARHP Annual Meeting
Rituximab Associated Late Onset Neutropenia – a Rheumatology Case Series and Review of the Literature
William Monaco¹, William F.C. Rigby² and Jonathan Jones³, ¹Internal Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Rituximab (RTX) has been associated with late onset neutropenia (LON), defined as an absolute neutrophil count (ANC) < 1.5 x 109/L at least 4 weeks…
Abstract Number: 2985 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Mofetil (MMF) Use in Systemic Sclerosis (SSc) Patients with a Designation of Elevated Systolic Pulmonary Artery Pressure (sPAP): Forced Vital Capacity (FVC), Outcomes and Survival from the European Scleroderma Trials and Research (EUSTAR) Database
Lesley Ann Saketkoo¹, Dörte Huscher², Christopher P. Denton³, Gabriela Riemekasten⁴, Virginia D. Steen⁵, Oliver Distler⁶ and EUSTAR member centres, ¹Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²Charité-University Hospital and German Rheumatism Research Centre, Berlin, Germany, ³Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁴Clinic of Rheumatology, University of Luebeck, Lübeck, Germany, ⁵Rheumatology, Georgetown University Medical Center, Washington, DC, ⁶Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, 8952 Schlieren, Switzerland
Background/Purpose : SSc related PH carries a high mortality; with SSc-PH related to restrictive lung disease (RLD) having worse prognosis and more rapid time to…
Abstract Number: 852 • 2015 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Early Systemic Sclerosis
Marie Hudson¹, Murray Baron², Mianbo Wang³, Candice Rabusa⁴, Susanna Proudman⁵, Mandana Nikpour⁶, Wendy Stevens⁴ and Canadian Scleroderma Research Group (CSRG), Australian Scleroderma Cohort Study (ASCS), ¹McGill University, Jewish General Hospital, Montreal, QC, Canada, ²Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁵Rheumatology Unit, Royal Adelaide Hospital North Terrace, Adelaide, Australia, ⁶University of Melbourne Department of Medicine, Melbourne, Australia
Background/Purpose: Health-related quality of life (HRQoL) research is a priority in systemic sclerosis (SSc). Yet, much of the data comes from prevalent cohorts with established…
Abstract Number: 2986 • 2015 ACR/ARHP Annual Meeting
Systemic Sclerosis Patients on Intensive Care Unit – Reasons for Admission and Determinants of Outcome
Svetlana I. Nihtyanova¹, Francesco Figorilli², Christopher P. Denton³, Banwari Agarwal² and Voon H. Ong¹, ¹Rheumatology, UCL Division of Medicine, London, United Kingdom, ²ITU, Royal Free Hospital, London, United Kingdom, ³Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Little has been published on systemic sclerosis (SSc) patients requiring admission to Intensive Care Unit (ICU) for organ support; published results suggest respiratory failure…
Abstract Number: 921 • 2015 ACR/ARHP Annual Meeting
Poverty Associated with Increase in Damage in SLE over Two-Year Period
Edward H. Yelin¹, Laura Trupin², Jinoos Yazdany² and Stephanie Rush³, ¹University of California, San Francisco, San Francisco, CA, ²Rheumatology, UCSF, SF, CA, ³UCSF, SF, CA
Background/Purpose: Prior research has shown that persons with SLE in poverty have fewer physician visits for SLE and receive lower technical quality of care.…
Abstract Number: 3068 • 2015 ACR/ARHP Annual Meeting
Damage Assessment in Takayasu’s Arteritis
Antoine G. Sreih¹, Tanaz A. Kermani², David Cuthbertson³, Simon Carette⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁵, Carol McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Christian Pagnoux¹¹, Philip Seo¹², Kenneth J. Warrington¹³, Steven R. Ytterberg¹⁴ and Peter A. Merkel⁸, ¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of California Los Angeles, Santa Monica, CA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶McMaster University, Hamilton, ON, Canada, ⁷Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹²Division of Rheumatology, Johns Hopkins, Baltimore, MD, ¹³Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: This study aimed to describe disease-related damage in Takayasu's arteritis (TAK) and evaluate damage assessment tools using data from a large longitudinal cohort. …
Abstract Number: 1225 • 2015 ACR/ARHP Annual Meeting
Long-Term Use of Biological Therapy and Discontinuation Rates in Rheumatoid Arthritis – Real World Patient Data
Laurent Chanroux, Joan Casellas and Fara Mboge, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Biologics (bDMARDs) have been shown to control disease progression in RA however there is still no cure for the disease and in many cases…
Abstract Number: 3207 • 2015 ACR/ARHP Annual Meeting
Axial Disease in Psoriatic Arthritis: A Clinical and Radiographic Comparison with Ankylosing Spondylitis
Deepak R. Jadon¹, Raj Sengupta¹, Alison L Nightingale², Mark Lindsay³, Eleanor Korendowych¹, Graham Robinson⁴, Amelia Jobling⁵, Gavin Shaddick⁶, Anne Barton⁷ and Neil J. McHugh⁸, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³Pharmacy & Pharmacology, University of Bath, Bath, United Kingdom, ⁴Royal United Hospital, Bath, United Kingdom, ⁵Mathematical Sciences, University of Bath, Bath, United Kingdom, ⁶Department of Mathematics, University of Bath, Bath, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom, ⁸Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom
Background/Purpose: Little is known of the characteristics of psoriatic spondyloarthritis (PsSpA). A study was conducted to determine the: (i) prevalence of PsSpA in a psoriatic…
Abstract Number: 1286 • 2015 ACR/ARHP Annual Meeting
Persistent Individual and Neighborhood Poverty Are Independent Risk Factors for Accumulated Lupus Damage
Laura Trupin¹, Stephanie Rush², Jinoos Yazdany³ and Edward H. Yelin⁴, ¹Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ²UCSF, SF, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, UC San Francisco, San Francisco, CA
Title: Persistent Individual and Neighborhood Poverty Are Independent Risk Factors for Accumulated Lupus Damage Background/Purpose: Previous research in systemic lupus erythematosus (SLE) has shown that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.